STAMFORD, Conn., April 05, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology
company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively
targeting peripheral kappa opioid receptors, today announced the closing of its underwritten public offering of 5,117,500 shares of
its common stock at a public offering price of $18.00 per share, which included 667,500 shares sold pursuant to the full exercise
by the underwriters of their option to purchase additional shares. The gross proceeds from the offering, before deducting the
underwriting discounts and commissions and offering expenses payable by Cara Therapeutics, are expected to be approximately $92.1
million.
The proceeds of the offering are expected to be used to fund the company’s clinical and research development activities,
including the completion of the Phase 3 program for I.V. CR845 in uremic pruritus, two Phase 3 trials of I.V. CR845 in acute pain
and a Phase 2b trial of oral CR845 in osteoarthritis pain, as well as for working capital and general corporate purposes.
Piper Jaffray & Co. and Stifel acted as joint book-running managers for the offering. Canaccord Genuity Inc., Needham &
Company, LLC, Janney Montgomery Scott LLC and H.C. Wainwright & Co., LLC acted as co-managers.
The offering was made only by means of a written prospectus forming part of a shelf registration statement previously filed with
and declared effective by the Securities and Exchange Commission (SEC). Copies of the prospectus supplement and the accompanying
prospectus relating to the offering may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at prospectus@pjc.com, or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or jurisdiction.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara Therapeutics is developing
a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial
efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with
currently available pain therapeutics.
CORPORATE CONTACT: Derek Chalmers, Ph.D., D.Sc. President & CEO Cara Therapeutics, Inc. 203-406-3700 MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 astarr@6degreespr.com INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 michael@sternir.com
